METHOD FOR OPTIMIZATION OF EARLY IMMUNOLOGICAL DIAGNOSTICS OF COMPLICATIONS OF PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH IHD Russian patent published in 2019 - IPC G01N33/48 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely cardiology, and can be used for optimization of early diagnosing complications of percutaneous coronary intervention in patients with ischemic heart disease (IHD). That is ensured by determining a myocardial damage marker – serum troponin T 1 days after the percutaneous coronary intervention in the blood and blood myoglobin (Mg) and MB creatine kinase fraction (CK-MB) are calculated by linear regression equations. If CK-MB 0.1–4.94 and Mg 25.0–72.0, the favorable course of the percutaneous coronary intervention is diagnosed in the patients with ischemic heart disease without developing the minor myocardial injury (MMI) syndrome, and if CK-MB 4.95–14.82 and Mg 72.1–216.0, the unfavorable course of the percutaneous coronary intervention in the patients with ischemic heart disease is diagnosed with developing MMI syndrome.

EFFECT: method enables optimizing the early diagnosis of the percutaneous coronary intervention complications in the patients with IHD in determining the blood in the blood of one marker with mathematical calculation of the rest with reducing the material costs and the study time.

1 cl, 2 tbl, 4 ex